Molecular targeting agents that inhibit EGF/EGFR or VEGF/VEGFR pathway such as erlotinib, gefinitib and bevacizumab however failed to produce clinical benefits (Govindan et al. 2005; Garland et al. 2007; Dowell et al. 2012; Ceresoli et al. 2013), but an inhibitor to block the HGF/c-Met pathway has not yet been examined for the efficacy to mesothelioma. This evidence concerns the gene KDR and mesothelioma.